Table 1.
Characteristics of included studies
| Author | Sample size | Age (years) | Gender (M:F) | Design | Scar type | Intervention Arm (n) | Control Arm (n) | Dose frequency | Outcome type | Follow up (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| Zahorec et al (2020) Slovakia | 8 | 9 to 42 | n/a | NCT | Post burn scars | ADSCs (8) | None | Varied | VSS | 6 |
| Eitta et al (2019) Egypt | 10 | 33.20 (±6.51) | 1:9 | NCT | Post acne scars | SVF (5) | FxCR (5) | Single | Scar area percentage, Patient self-assessment and satisfaction | 3 |
| L’Orphelin et al (2020) France | 43 | n/a | n/a | Retrospective study | Acquired or congenital scars | Fat graft (55) | n/a | Single | Patient and surgeon satisfaction | 6 |
| Elkahky et al (2016) Egypt | 20 | 20-45 | 7:13 | RCT | Post acne scars | SVF (10) | PRP (10) | Single | Surface area of scars | 3 |
| Lee et al (2018) Korea | 17 | 37 (14-74) | 12:5 | Retrospective Study-study 1 | Diverse distribution | SVF (17) | n/a | Single | OSAS, VSS, VAS | 6 |
| 15 | 34 (14-65) | 12:3 | Retrospective Cohort Study 2 | Face | SVF (7) | Control (8) | OSAS, VSS, VAS | |||
| Bhoosan et al (2019) India | 34 | 32.2 (±12) | 22:12 | Prospective study | Post traumatic scars | Nano-fat graft (34) | None | Single | POSAS | 3 |
| Rao et al (2020) India | 60 | 30.8 (±9.8) | 4:32 | Prospective study | Facial scars | Nano-fat graft (30) | Non nano-fat (unclear) (30) | Single dose in 83.3% | VAS | 12 |
| Svolacchia et al (2015) Italy | 3 | 28-36 | 1:02 | Case series | Hypertrophic scar or keloids | Nano fat graft (micro fat graft) (3) | None | Single | VSS | 24 |
| Pallua et al (2014) Germany | 26 | 22-64 | 10:16 | Prospective study | Facial scars | Fat graft (26) | None | Single | POSAS | 1 |
| Klinger et al (2013) Italy | 20 | 38.3 (±12.4) | Not clear | Prospective study | Post traumatic scars | Fat graft (20) | Placebo (Normal saline) (20) | Single | POSAS | 3 |
| Kim et al (2011) Korea | 31 | 39.5 | 14:17 | NCT | Depressed scars | ADSCs (31) | None | Single | Scar volume | 3 |
| Zhou et al (2016) China | 22 | 36.4 | 10:12 | NCT | Post acne | ADSC + FxCR (22) | FxCR (22) | Single | Subjective satisfaction Scale | 3 |
| Gentile et al (2014) Italy | 20 | 21-69 | na | NCT | Post burn and post traumatic | SVF enriched fat graft (10) | Fat graft with PRP (10) | Single | Process description | 12 |
| Jaspers et al (2015) Netherlands | 40 | 45 (±15.3) | 9:31 | Prospective study | Post surgical and post skin graft | Fat graft (40) | None | Single | POSAS | 3 |
| Tenna et al (2017) Italy | 30 | 18-52 | n/a | RCT | Acne scars | Nanofat + PRP + FxCR (15) | Nanofat + PRP (15) | Single | Ultrasound scar thickness, satisfaction | 6 |
| Jan et al (2018) Pakistan | 48 | 22.25 (±5.79) | 20:28 | Prospective study | Post burn facial scars | Nanofat graft (48) | None | Single | POSAS | 6 |
| Kim et al (2019) Korea | 1 | 21 | Male | Case report | Hypertrophic scars | SVF + FxCR (1) | na | Single SVF and FxCR | Photography | 12 |
| Carstens et al (2017) Nicaragua | 5 | 18-37 | 2:3 | Case series | Post burn fibrosis | SVF (5) | None | Single | VSS | 6 |
| Amir Bajouri et al (2018) Iran | 20 | na | na | RCT | Post burn scars | SVF (20) | Normal saline (20) | Single | VSS | 4 |
| Kwon et al (2023) | 20 | 19-65 | Revision scars | SVF | Normal saline | POSAS | 6 |
Abbreviations: NCT = non-randomized clinical trial, RCT = Randomized clinical trial, SVF = Stromal vascular fraction, FxCR = Fractionated cryotherapy, VSS = Vancouver scar scale, POSAS = Patients and Observers Scar Assessment Score, ADSC = Adipose derived stem cells, PRP = Platelet rich plasma, HTS = Hypertrophic scar, Msc = Mesenchymal stem cells.